Wei-Ting Hwang

Science Translational Medicine · 2004–2020

A researcher in the Science corpus: 8 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Whom Wei-Ting Hwang trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. Douglas G. Altman
  2. Julian P. T. Higgins
  3. S. Thompson

Who trusts Wei-Ting Hwang overall

  1. Jennifer N. Brudno

Papers from Wei-Ting Hwang's perspective

Ordered by how strongly the researchers Wei-Ting Hwang trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Quantifying heterogeneity in a meta‐analysis (Statistics in Medicine)
  2. Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia (New England Journal of Medicine)
  3. A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer (Clinical Cancer Research)
  4. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia (Science Translational Medicine)
  5. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia (Nature)
  6. HER2-Specific Chimeric Antigen Receptor–Modified Virus-Specific T Cells for Progressive Glioblastoma (JAMA Oncology)
  7. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate… (Journal of Clinical Oncology)
  8. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. (Journal of Clinical Investigation)
  9. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. (Journal of Clinical Investigation)
  10. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. (Blood)

Their papers